Theravance Newswire

Comprehensive Real-Time News Feed for Theravance.

Results 1 - 20 of 121 in Theravance

  1. GlaxoSmithKline And Theravance: The Asthma Approval In FiguresRead the original story w/Photo

    Friday May 1 | Seeking Alpha

    Based on the resulting figures, GSK's partner Theravance seems to trade at a large discount to its intrinsic value. Yesterday, Breo was approved for the treatment of asthma in adult patients, but not in adolescents.

    Comment?

  2. FDA approves Glaxo, Theravance's Breo Ellipta asthma drugRead the original story w/Photo

    Friday May 1 | Fox News

    The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger asthma sufferers.

    Comment?

  3. Theravance Biopharma To Report First Quarter 2015 Financial Results On May 7, 2015Read the original story

    Thursday Apr 30 | BioSpace

    Theravance Biopharma, Inc. today announced that it will release financial results for the period ended March 31, 2015 after market close on Thursday, May 7, 2015. An accompanying conference call will be held at 5:00 pm EDT.

    Comment?

  4. Theravance Biopharma To Present At Bank of America Merrill Lynch 2015 Health Care ConferenceRead the original story

    Thursday Apr 30 | BioSpace

    Theravance Biopharma, Inc. announced today that Rick E Winningham, Chairman and Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, at 3:00 p.m. PDT. The conference will be held from May 12-14 at the Encore at the Wynn Las Vegas, Las Vegas, NV.

    Comment?

  5. FDA Approves Glaxo', Theravance's Breo Ellipta Asthma DrugRead the original story w/Photo

    Friday May 1 | Medical Daily

    The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger asthma sufferers.

    Comment?

  6. Us Fda approves Glaxo, Theravance's Breo Ellipta asthma drugRead the original story w/Photo

    Friday May 1 | Channelnewsasia.com

    The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. REUTERS: The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said.

    Comment?

  7. FDA approves expansion of GSK inhaler to fight asthmaRead the original story w/Photo

    Friday May 1 | Local Tech Wire

    ... a steroid and a beta agonist. London-based Glaxo pays royalties on Breo Ellipta to the drug's co-developer Theravance Inc., which is based in San Francisco. Michael Aguiar, Theravance's CEO,. pointed out: "We believe the approval of Breo Ellipta as ...

    Comment?

  8. Fda Approves Breo Ellipta For The Treatment Of Adults With Asthma In The UsRead the original story

    Thursday Apr 30 | BioSpace

    /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREOA ELLIPTAA (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of ...

    Comment?

  9. GSK wins approval for asthma drug; will be produced in ZebulonRead the original story w/Photo

    Thursday Apr 30 | Business Journal

    ... produced Advair. London-based Glaxo announced the approval from the U.S. Food and Drug Administration alongside Theravance, Inc. (Nasdaq: THRX), which is in line to receive some royalty revenue on sales of the treatment. GSK shares traded up ...

    Comment?

  10. Fda approves Breoa Elliptaa for the treatment of adults with asthma in the UsRead the original story

    Thursday Apr 30 | Freshnews

    GlaxoSmithKline plc and Theravance, Inc. today announced that the US Food and Drug Administration has approved BREO ELLIPTA for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the relief of acute bronchospasm.

    Comment?

  11. Theravance To Report First Quarter 2015 Financial Results On May 6, 2015Read the original story

    Wednesday Apr 29 | BioSpace

    Theravance, Inc. announced today that it will report financial results for the first quarter ended March 31, 2015 after market close on Wednesday, May 6, 2015. Theravance management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.

    Comment?

  12. Ten Top Dividend Healthcare Dogs Post 10% To 23% April UpsidesRead the original story w/Photo

    Wednesday Apr 29 | Seeking Alpha

    ... Top two healthcare sector stocks by yield were biotechnology firms PDL BioPharma, Inc. (NASDAQ: PDLI ) [1] and Theravance, Inc. (NASDAQ: THRX ) [2]. The best of six drug manufacturers - major placed third, GlaxoSmithKline PLC (NYSE: GSK ) [3]. The ...

    Comment?

  13. ViaSat - Building Tomorrow's Broadband Toll RoadsRead the original story w/Photo

    Tuesday Apr 14 | Seeking Alpha

    ... but the theme in Klarman's holdings is a lack of profitability. ViaSat, Cheniere Energy (NYSEMKT: LNG ), Theravance (NASDAQ: THRX ) and other of Klarman's larger holdings are either relatively or completely devoid of any profits. Instead, their ...

    Comment?

  14. Theravance Biopharma To Present At The Needham Healthcare ConferenceRead the original story

    Tuesday Apr 7 | BioSpace

    Theravance Biopharma, Inc. announced today that Rick E Winningham, Chairman and Chief Executive Officer, is scheduled to present at the 2015 Needham Healthcare Conference on Tuesday, April 14, 2015, at 8:00 a.m. EDT. The conference will be held from April 14-15 in New York at the Westin Grand Central Hotel.

    Comment?

  15. Theravance Announces New Employment Inducement AwardsRead the original story

    Sunday Apr 5 | BioSpace

    Theravance Biopharma, Inc. announced today that stock options to purchase an aggregate of 45,700 of the Company's ordinary shares were granted to six new non-executive officer employees on April 1, 2015. The options were granted in accordance with NASDAQ Listing Rule 5635 under the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan , which the Board of Directors of Theravance Biopharma adopted in October 2014 to facilitate the granting of equity awards to new employees.

    Comment?

  16. 10 Top Dividend Healthcare Dogs Declare 5% To 20% March UpsidesRead the original story w/Photo

    Apr 1, 2015 | Seeking Alpha

    ... Top two healthcare sector stocks by yield were biotechnology firms, PDL BioPharma, Inc. (NASDAQ: PDLI ) [1] and, Theravance Inc. (NASDAQ: THRX ) [2]. The best of six drug manufacturers - major placed third, GlaxoSmithKline PLC (NYSE: GSK ) [3]. The ...

    Comment?

  17. Volatile Theravance Inc. Offers Attractive Total Returns PotentialRead the original story w/Photo

    Mar 30, 2015 | Seeking Alpha

    ... campaign, as well as from improving insurance coverage. A huge potential target market has earned the company Theravance, Inc. (NASDAQ: THRX ), a relatively large market cap and drawn the interest of several large institutional investors; four ...

    Comment?

  18. GSK And Theravance: Implications Of The Advisory Panel DecisionRead the original story w/Photo

    Mar 21, 2015 | Seeking Alpha

    ... further large safety studies to be conducted post-marketing. The drug is co-developed by GSK (NYSE: GSK ) and Theravance (NASDAQ: THRX ) and is already approved for asthma in Japan. In Europe it is approved for asthma in patients above age 12 (and ...

    Comment?

  19. Theravance Announces Trading In Common Stock HaltedRead the original story

    Mar 19, 2015 | BioSpace

    Theravance, Inc. announced today that NASDAQ halted trading of the Company's common stock this morning, March 19, 2015. The U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will meet today to discuss the supplemental New Drug Application 204275-S001 for fluticasone furoate and vilanterol dry powder for inhalation for the once-daily treatment of asthma in patients aged 12 years and older.

    Comment?

  20. GlaxoSmithKline And Theravance Announce Outcome Of Us Fda Advisory...Read the original story

    Mar 19, 2015 | BioSpace

    GlaxoSmithKline plc and Theravance, Inc. today announced the outcome of the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the United States Food and Drug Administration regarding the supplemental New Drug Application for BREO ELLIPTA as a once-daily inhaled treatment for asthma in patients aged 12 years and older. The FDA Advisory Committee voted that the efficacy and safety data for FF/VI 100/25 mcg and 200/25 mcg once daily in asthma support approval in adults 18 years of age and older .

    Comment?